Asian Medtech Associations Reg Networking: COVID-19 Dominates As Medtechs Seek Return To Normality – Part One

 
• By Ashley Yeo

The Asian Medtech Associations Regulatory Networking discussions this month centered on strategies to control COVID-19 in Thailand, Singapore, South Korea, Indonesia and Vietnam. This editorial feature is hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy and the Asia Regulatory Professional Association. This is the first of two articles from the discussions.

Asia flags

The focus in Asian countries, as elsewhere in recent weeks, has been on building and supporting the necessary health care strengths, stocks and staffing skills to secure sustainable control of the COVID-19 pandemic.

Addressing the latest Asian Medtech Associations Reg Networking discussions, ThaiMed, whose chairman currently heads ASEANMed (the ASEAN Federation of Medical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Asia

More from Geography

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 
• By Natasha Barrow

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 
• By Natasha Barrow

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.